Xeris Pharmaceuticals, Inc. (XERS): Price and Financial Metrics
XERS Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for XERS is 0.03 -- better than only 8.65% of US stocks.
- XERS's went public 1.46 years ago, making it older than only 1.68% of listed US stocks we're tracking.
- With a price/sales ratio of 121.31, Xeris Pharmaceuticals Inc has a higher such ratio than 98.32% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Xeris Pharmaceuticals Inc, a group of peers worth examining would be KPTI, PZG, OCUL, XPL, and CLSN.
- XERS's SEC filings can be seen here. And to visit Xeris Pharmaceuticals Inc's official web site, go to www.xerispharma.com.
XERS Stock Price Chart More Charts
XERS Price/Volume Stats
Xeris Pharmaceuticals, Inc. (XERS) Company Bio
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company’s lead product candidate is glucagon rescue pen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise self-administered glucagon that is in Phase IIa clinical trials for the treatment of post-bariatric hypoglycemia; continuous glucagon, which is in Phase II clinical trials for the treatment of congenital hyperinsulinism; continuous glucagon that is in Phase IIa clinical trials for the treatment of hypoglycemia-associated autonomic failure; self-administered glucagon, which is in Phase IIa clinical trials for the treatment of exercise-induced hypoglycemia; and ready-to-use glucagon that is in Phase II clinical trials for use in a bi-hormonal artificial pancreas closed-loop systems. The company’s preclinical programs include ready-to-use diazepam, a ready-to-use diazepam formulation for the treatment of ARS in patients with epilepsy; and pram-insulin, a ready-to-use fixed dose combination of insulin and pramlintide. It serves patients, caregivers, and health practitioners. The company was founded in 2005 and is based in Chicago, Illinois.